Pyxis Oncology (PYXS) Share-based Compensation (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Share-based Compensation data on file, last reported at $2.1 million in Q4 2025.

• Share-based Compensation for Q4 2025 came in at $2.1 million, down 24.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.8 million (down 8.84% YoY), and the FY2025 annual result was $11.8 million, down 8.84% from the prior year.
• Share-based Compensation declined to $2.1 million in Q4 2025 per PYXS's latest filing, from $3.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $6.4 million in Q4 2022 and troughed at $307000.0 in Q3 2021.
• A 5-year average of $3.2 million and a median of $3.1 million in 2021 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2021 and 2023: Share-based Compensation soared 28390.91% in 2021, then tumbled 50.08% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $3.1 million in 2021, then soared by 106.94% to $6.4 million in 2022, then plunged by 50.08% to $3.2 million in 2023, then decreased by 13.75% to $2.8 million in 2024, then retreated by 24.92% to $2.1 million in 2025.
• Business Quant data shows PYXS's Share-based Compensation at $2.1 million in Q4 2025, $3.1 million in Q3 2025, and $3.0 million in Q2 2025.